Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F25%3A00647468" target="_blank" >RIV/68081707:_____/25:00647468 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B978044321790600002X?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B978044321790600002X?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-443-21790-6.00002-X" target="_blank" >10.1016/B978-0-443-21790-6.00002-X</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling

Popis výsledku v původním jazyce

The aryl hydrocarbon receptor (AhR) is a transcription factor belonging to the basic helix-loop-helix Per-ARNT-Sim family of transcriptional regulators and a major regulator of xenobiotic metabolism. AhR and its target genes have been found to be deregulated in a number of cancer types, which has been linked with cancer development and progression. Nevertheless, upregulation of several xenobiotic-metabolizing enzymes and transporters via AhR signaling, which is observed in some cancer types, also has the potential to alter the metabolism and efflux of anticancer drugs. Herein, we provide a short overview of the current understanding of the potential impact of deregulated AhR expression and activity on drug metabolism in cancer cells. We focus primarily on established AhR gene targets, including phase I enzymes such as cytochrome P450 family 1 enzymes. Furthermore, this chapter is intended to provide a broader overview of the impact of AhR signaling alterations that have been uncovered in tumor cells.

Název v anglickém jazyce

Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling

Popis výsledku anglicky

The aryl hydrocarbon receptor (AhR) is a transcription factor belonging to the basic helix-loop-helix Per-ARNT-Sim family of transcriptional regulators and a major regulator of xenobiotic metabolism. AhR and its target genes have been found to be deregulated in a number of cancer types, which has been linked with cancer development and progression. Nevertheless, upregulation of several xenobiotic-metabolizing enzymes and transporters via AhR signaling, which is observed in some cancer types, also has the potential to alter the metabolism and efflux of anticancer drugs. Herein, we provide a short overview of the current understanding of the potential impact of deregulated AhR expression and activity on drug metabolism in cancer cells. We focus primarily on established AhR gene targets, including phase I enzymes such as cytochrome P450 family 1 enzymes. Furthermore, this chapter is intended to provide a broader overview of the impact of AhR signaling alterations that have been uncovered in tumor cells.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Resistance in Hematologic Malignancies and Cancer

ISBN

978-0-443-21790-6

Počet stran výsledku

21

Strana od-do

215-235

Počet stran knihy

326

Název nakladatele

Elsevier

Místo vydání

Nizozemsko

Kód UT WoS kapitoly

—